Holen Sie sich die Stockscreener-App
2.45
4.70%
0.11
Handel nachbörslich:
2.40
-0.05
-2.04%
Schlusskurs vom Vortag:
$2.34
Offen:
$2.35
24-Stunden-Volumen:
296.02K
Relative Volume:
0.31
Marktkapitalisierung:
$19.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.84M
KGV:
-0.3323
EPS:
-7.3739
Netto-Cashflow:
$-18.59M
1W Leistung:
+3.81%
1M Leistung:
-20.71%
6M Leistung:
-22.96%
1J Leistung:
+541.03%
1-Tages-Spanne:
$2.20
$2.50
1-Wochen-Bereich:
$2.20
$2.50
52-Wochen-Spanne:
$0.2803
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
2.45 | 18.70M | 0 | -20.84M | -18.59M | -7.3739 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Number of shareholders of Cellectar Biosciences, Inc. – MUN:NV40 - TradingView
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38Swing Entry Signals - newsline.com
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesProfit Announcement - newsline.com
[EFFECT] Cellectar Biosciences, Inc. SEC Filing - Stock Titan
Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named - Stock Titan
Cellectar plans phase 3 trial for WM treatment after BTKi - Investing.com UK
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting - Investing News Network
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com - Investing.com South Africa
Cellectar Biosciences Q1 2026 earnings preview - MSN
Cellectar (NASDAQ: CLRB) details 51.9M-share resale tied to May 2026 financing - Stock Titan
Cellectar Biosciences (CLRB) upgraded to buy: Here's what you should know - MSN
Large warrant exercise and equity plan votes ahead for Cellectar (NASDAQ: CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Edges Higher: Support Levels Tested as Biotech Sector Shows Mixed SignalsFundamental Weighted - newsline.com
Cellectar Biosciences Edges Higher, Finding Support Near $3.04Growth Stock Picks - The Legal Advocate
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar Biosciences Announces Board Changes and New Director - The Globe and Mail
Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan
Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView
Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan
Cellectar Biosciences, Inc. Announces Board Changes - marketscreener.com
User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN
CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing - Minichart
Cellectar Biosciences, Inc.Common Stock (NQ: CLRB - FinancialContent
What's Going With Cellectar Biosciences Stock On Wednesday? - MSN
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Cellectar Biosciences Signals Pivotal Turn in Earnings Call - TipRanks
Cellectar Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing - GuruFocus
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 - MSN
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress - Investing.com UK
Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202 - GuruFocus
Cellectar Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress By Investing.com - Investing.com Nigeria
CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum - TradingView
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cellectar Biosciences Inc-Aktie (CLRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
May 07 '26 |
Buy |
2.88 |
8,680 |
24,998 |
20,318 |
| NEIS JOHN | Director |
Dec 12 '25 |
Sale |
3.70 |
198 |
732 |
10 |
| CARUSO JAMES V | Chief Executive Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
11,638 |
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):